Related Experiment Video
Updated: Mar 5, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell
Gõkhan Metan1, Leylagül Kaynar2, Nuran Yozgat3
1Departments of Infectious Diseases, Erciyes University Faculty of Medicine, Kayseri, Turkey.
A new antibiotic stewardship program in haematopoietic stem cell transplantation (HSCT) reduced carbapenem use by 90%. This strategy effectively managed febrile neutropenia while decreasing overall antibiotic consumption.
Area of Science:
- Infectious Diseases
- Hematology
- Antimicrobial Stewardship
Background:
- High rates of carbapenem-resistant Gram-negative bacilli infections in febrile neutropenic patients necessitate optimized treatment strategies.
- Previous empirical antibiotic regimens in haematopoietic stem cell transplantation (HSCT) settings contributed to rising antimicrobial resistance.
- The need for evidence-based guidelines to manage neutropenic fever while conserving broad-spectrum antibiotics is critical.
Purpose of the Study:
- To evaluate the impact of a two-stage intervention on antibiotic use in febrile neutropenic patients undergoing HSCT.
- To assess the effectiveness of a revised empirical antibiotic pathway in reducing carbapenem consumption.
- To analyze changes in antimicrobial resistance patterns and patient outcomes following the intervention.
Main Methods:
- Implementation of a two-stage intervention, shifting from carbapenems to piperacillin/tazobactam (TZP) for empirical neutropenic fever treatment.
- Defined criteria for escalating or de-escalating antibiotic therapy based on clinical status and microbiological data.
- Calculation of antibiotic consumption using defined daily dosages (DDD) per 1000 patient days for 2013 and 2014.
Main Results:
- Significant reduction in carbapenem (imipenem, meropenem) use by over 90% from 2013 to 2014 (p<0.001).
- Increased use of piperacillin/tazobactam (TZP) and amikacin, indicating a shift in empirical therapy (p<0.001).
- A decrease in the number of patient deaths during hospitalization from 24 in 2013 to 17 in 2014.
Conclusions:
- A febrile neutropenia pathway guided by local epidemiology and international guidelines can significantly reduce antibiotic use in HSCT patients.
- The intervention demonstrated success in optimizing antibiotic selection without compromising patient outcomes.
- Sustaining such antimicrobial stewardship initiatives requires robust multidisciplinary collaboration.
More Related Videos
09:29Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
Published on: February 1, 2013
08:30One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Pharmacokinetics in Pediatric Patients: Drug Excretion